Trial Profile
Phase I/II Study Assessing Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Primary Lung Cancer With Durvalumab After Definitive Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Nov 2022 Planned End Date changed from 1 Apr 2024 to 1 Mar 2026.
- 04 Nov 2022 Planned primary completion date changed from 1 Apr 2023 to 1 Mar 2026.
- 27 Jul 2021 Status changed from not yet recruiting to recruiting.